Our novel secretome ST266 provides the opportunity to pursue treatments for numerous complex disorders across multiple disease areas. To date, we have completed three Phase I studies of ST266. We are initiating a Phase II clinical trial for the treatment of periodontitis, while exploring robust preclinical validation in several additional indications.

*Periodontitis is serious inflammation of the gums that damages the soft tissue and destroys the bone that supports your teeth.